Management of type 2 diabetic patients in primary care in Spain;Tratamiento de los pacientes con diabetes mellitus tipo 2 en atención primaria en España

Medicina Clinica

Volumn 125, Issue 5, 2005, Pages 166-172

  Arroyo, Jaime ^a   Badía, Xavier ^b   De La Calle, Hermenegildo ^c   Díez, Javier ^d   Estmatjes, Enric ^e   Fernández, Isabel ^f   Filozof, Claudia ^g,l   Franch, Josep ^h   Gambús, Gemma ⁱ   Gomis, Ramón ^e   Navarro, Javier ^j   De Pablos, Pedro ^k  

^a CAP Sant Felix   (Spain)

^b Health Outcomes Research Europe   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Centro de Salud Tafalla   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Centro de Salud de Camas   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h Centre d Assistència Primària Raval Sud   (Spain)

ⁱ Departamento Médico de Novartis Farmacéutica   (Spain)

^j Centro de Salud Nazaret   (Spain)

^k Hospital Nuestra Senora del Pino   (Spain)

^l Hospital Virgen del Pino ^*  (Spain)

more..

Author keywords

Hypoglycaemia; Medical costs; Metabolic control; Microvascular and macrovascular complications; NIDDM; Oral antidiabetic agents; Quality of life

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIMARY MEDICAL CARE; QUALITY OF LIFE; SPAIN; VASCULAR DISEASE;

EID: 23444447566     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13077139     Document Type: Article

References (42)

1. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-97.
2. Alberti KGM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Provisional Report of WHO consultation. Diabet Med. 1998;15:539-53.
3. Fernández Castañer M. Nuevos criterios de diagnóstico y clasificación de la diabetes mellitus. Endocrinología. 1998;45:107-10.
4. Muñiz J, Cordido F, López Rodríguez I, Castro Beiras A. Effect of the application of the new diagnostic criteria of diabetes in the prevalence estimates and diagnostic level in the general population. European J Pub Health. 1999;9:149-51.
5. Castells C, Treserras R, Serra J, Goday A, Loveras G, Salleras L. Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. Diabetes Res Clin Pract. 1999;43:33-40.
6. De Pablos-Velasco PL, Martínez-Martín FJ, Rodríguez-Pérez F, Anía BJ, Losada A, Betancor P. Prevalence and determinants of diabetes mellitus and glucose intolerance in a Canarian Caucasian population- Comparison of the 1997 ADA and the 1985 WHO criteria. The Guia Study. Diabet Med. 2001;18:235-41.
7. Soriguert F, Esteva I, Rojo-Martínez G, Ruiz de Adana S, Caala M, Merelo MJ, et al, Diabetes Group of the Andalusian Society of Endocrinology and Nutrition. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract. 2002;56:213-20.
8. Franch J, Álvarez F, Diego F, Hernández R, Cueto A. Epidemiología de la diabetes mellitus en la provincia de León. Med Clin (Barc). 1998;91:401-5
9. Goday A, Serrano Ríos M. Epidemiología de la Diabetes Mellitus en España. Revisión crítica y nuevas perspectivas. Med Clin (Barc). 1994;102:306-15.
10. Cerveny JD, Leder RD, Weart CW. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus. Ann Pharmacother. 1998;32:896-905.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-53
12. Hart WM, Espinosa C, Rovira J. El coste de la diabetes mellitus conocida en España. Med Clin (Barc). 1997;109:289-93.
13. Pascual JM, González C, De Juan S, Sánchez C, Sánchez B, Pérez M. Impacto de la diabetes mellitus en los costes de hospitalización. Med Clin (Barc). 1996;207-10.
14. Mata M, Antonanzas S, Tafalla M, Sanz P. The cost of type 2 diabetes in Spain. Gac Sanit. 2002;16:511-20.
15. Bradley C, Gamsus DS. Guidelines for encouraging psychological well-being: report of a working group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med. 1994;11:510-6.
16. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care. 1998;21:C44-52.
17. UK prospective diabetes study group. Quality of life in type 2 diabetic patients affected by complications but no intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125-36.
18. Badia X, Roset M, Montserrat S, Herdman M, Segura A. La versión española del EuroQol: descripción y aplicaciones. Med Clin (Barc). 1999;112:S79-S86.
19. Bradley C, Todd C, Gorton T, Symonds E, Maartin A, Plowright R. The development of an individual questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL Qual Life Res. 1999;8:79-91.
20. Álvarez Gutiérrez EJ. El tabaquismo como problema de Salud Pública. En: Barrueco Ferrero M, Hernández Mezquita MA, Torrecilla García M, editores. Manual de prevención y tratamiento del tabaquismo. Madrid: Ed. Ergon; 2003. p. 27-68.
21. Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB. Smoking and mortality among women with type 2 diabetes: The Nurses'Health Study cohort. Diabetes Care. 2001;24:2043-8.
22. Chuahirun T, Khanna A, Kimball K, Wesson DE. Cigarette smoking and increased albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis. 2003;41:13-21.
23. Takeuchi N, Kawamura T, Kanai A, Nakamura N, Uno T, Hara T, et al. The effect of cigarette smoking on soluble adhesion molecules in middle-aged patients with Type 2 diabetes mellitus. Diabet Med. 2002;19:57-64.
24. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003;107:2435-9.
25. Kirk A, Mutrie N, MacIntyre P, Fisher M. Increasing physical activity in people with type 2 diabetes. Diabetes Care. 2003;26:1186-92.
26. Tremble JM. Is continuous weight gain inevitable in type 2 diabetes mellitus? JR Soc Health. 1999;119:235-9.
27. Williamson KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin actino in type 2 diabetes. Diabetes Obes Metab. 2000;2:121-9.
28. Williams G. Obesity and type 2 diabetes: a conflict of interests? Int J Obes Relat Metab Disord. 1999;23:S2-4.
29. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12.
30. Schatz H, Schoppel K, Lehwalder D, Schandry R. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes. 2003;111:262-6.
31. Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003;61:13-9.
32. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
33. De la Calle H, Costa A, Díez-Espino J, Franch J, Goday A. Evaluation on the compliance of the metabolic control aims in outpatients with type 2 diabetes mellitus in Spain. The TranS study. Med Clin (Barc). 2003;120:446-50
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
35. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 200;161:1653-9.
36. Morgan CL, Currie CJ, Stott NC, Smithers M, Butler CC, Peters JR. The prevalence of multiple diabetes-related complications. Diabet Med. 2000;17:146-51.
37. Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, et al. Cost effectiveness of an intensive blood glucosee control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320:1373-8.
38. Norris S, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, et al, and the Task Force on Community Preventive Services. Am J Prev Med. 2002;22:15-38.
39. Bjork S. The cost of diabetes and diabetes care. Diabetes research and diabetes care. Diabetes Research and Clinical Practice. 2001;54:S13-S8.
40. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-24.
41. Goddijn PP, Bilo HJ, Feskens EJ, Groeniert KH, Van der Zee KI, Meyboom-de Jong B. Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabet Med. 1999;16: 23-30.
42. Rubin RR, Peyrot M. Effect of education on lifestyle and self regulation intentions and behavior. Diabetes Metab Res Rev. 1999;15:205-18.